Share Prices & Company Research

Market News

01 Apr 2021 | 12:29

Pfizer-BioNTech Covid-19 vaccine 100% effective South African variant

(Sharecast News) - Updated trials results confirmed the high efficacy of the Covid-19 shot developed by Pfizer and BioNTech, including against the new strain of the virus first detected in South Africa, which is known as B1351. The new trial data, which included that for 12,000 people who had been vaccinated for up to six months, showed that the shot was 91.3% effective in preventing Covid-19.

In South Africa meanwhile, the vaccine showed 100% efficacy, although the number of trial participants from the African country was relatively small, at 800.

Pfizer and BioNTech were expected to file for full regulatory approval of the vaccine with the US Food and Drug Administration.

"[The trial data] provide the first clinical results that a vaccine can effectively protect against currently circulating variants, a critical factor to reach herd immunity and end this pandemic for the global population," said BioNTech chief Ugur Sahin.

No serious safety concerns were observed among trial participants.

Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.